Daniel J. Haders

This paper evaluates MDL-001, a broad-spectrum antiviral, showing potent in vitro and in vivo activity against influenza, RSV, SARS-CoV-2, and hepatitis B/C/D viruses, with improved efficacy compared to existing treatments.

AmesNet improves mutagenicity prediction by enhancing sensitivity without sacrificing balanced accuracy in novel chemical spaces.

This study uses GALILEO and ChemPrint to generate novel antiviral compounds targeting the conserved Thumb-1 site, achieving 100% hit rate in vitro against HCV and Coronavirus 229E.

The paper identifies the RdRp Thumb-1 pocket as a conserved target for broad-spectrum antivirals, validated through structural and biochemical analyses of multiple viruses.

ChemPrint improves drug discovery by enhancing hit rates and chemical novelty through a novel AI framework, achieving higher performance on challenging targets.